Alexander Kirichenko1, Olivier Gayou2, David Parda2, Vijay Kudithipudi2, Kusum Tom3, Akhtar Khan3, Peter Abrams3, Molly Szramowski3, Jose Oliva4, Dulabh Monga5, Moses Raj5, Ngoc Thai3. 1. Department of Oncology, Division of Radiation Oncology, Allegheny General Hospital, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA. Electronic address: akiriche@wpahs.org. 2. Department of Oncology, Division of Radiation Oncology, Allegheny General Hospital, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA. 3. Department of General Surgery, Division of Abdominal Transplant, Allegheny General Hospital, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA. 4. Division of Gastroenterology, Allegheny General Hospital, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA. 5. Division of Medical Oncology, Allegheny General Hospital, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.
Abstract
OBJECTIVES: We report single center experience on the outcome and toxicity of SBRT alone or in combination with surgery for inoperable primary and metastatic liver tumors between 2007 and 2014. PATIENTS AND METHODS: Patients with 1-4 hepatic lesions and tumor diameter ≤9 cm received SBRT at 46.8Gy ± 3.7 in 4-6 fractions. The primary end point was local control with at least 6 months of radiographic followup, and secondary end points were toxicity and survival. RESULTS: Eighty-seven assessable patients (114 lesions) completed liver SBRT for hepatoma (39) or isolated metastases (48) with a median followup of 20.3 months (range 1.9-64.1). Fourteen patients underwent liver transplant with SBRT as a bridging treatment or for tumor downsizing. Eight patients completed hepatic resections in combination with planned SBRT for unresectable tumors. Two-year local control was 96% for hepatoma and 93.8% for metastases; it was 100% for lesions ≤4 cm. Two-year overall survival was 82.3% (hepatoma) and 64.3% (metastases). No incidence of grade >2 treatment toxicity was observed. CONCLUSION: In this retrospective analysis we demonstrate that liver SBRT alone or in combination with surgery is safe and effective for the treatment of isolated inoperable hepatic malignancies and provides excellent local control rates.
OBJECTIVES: We report single center experience on the outcome and toxicity of SBRT alone or in combination with surgery for inoperable primary and metastatic liver tumors between 2007 and 2014. PATIENTS AND METHODS: Patients with 1-4 hepatic lesions and tumor diameter ≤9 cm received SBRT at 46.8Gy ± 3.7 in 4-6 fractions. The primary end point was local control with at least 6 months of radiographic followup, and secondary end points were toxicity and survival. RESULTS: Eighty-seven assessable patients (114 lesions) completed liver SBRT for hepatoma (39) or isolated metastases (48) with a median followup of 20.3 months (range 1.9-64.1). Fourteen patients underwent liver transplant with SBRT as a bridging treatment or for tumor downsizing. Eight patients completed hepatic resections in combination with planned SBRT for unresectable tumors. Two-year local control was 96% for hepatoma and 93.8% for metastases; it was 100% for lesions ≤4 cm. Two-year overall survival was 82.3% (hepatoma) and 64.3% (metastases). No incidence of grade >2 treatment toxicity was observed. CONCLUSION: In this retrospective analysis we demonstrate that liver SBRT alone or in combination with surgery is safe and effective for the treatment of isolated inoperable hepatic malignancies and provides excellent local control rates.
Authors: David L Andolino; Cynthia S Johnson; Mary Maluccio; Paul Kwo; A Joseph Tector; Jennifer Zook; Peter A S Johnstone; Higinia R Cardenes Journal: Int J Radiat Oncol Biol Phys Date: 2011-06-07 Impact factor: 7.038
Authors: Rojymon Jacob; Falynn Turley; David T Redden; Souheil Saddekni; Ahmed K A Aal; Kimberly Keene; Eddy Yang; Jessica Zarzour; David Bolus; J Kevin Smith; Stephen Gray; Jared White; Devin E Eckhoff; Derek A DuBay Journal: HPB (Oxford) Date: 2014-09-04 Impact factor: 3.647
Authors: F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts Journal: Hepatology Date: 2001-06 Impact factor: 17.425
Authors: Thomas A Aloia; Jean-Nicolas Vauthey; Evelyne M Loyer; Dario Ribero; Timothy M Pawlik; Steven H Wei; Steven A Curley; Daria Zorzi; Eddie K Abdalla Journal: Arch Surg Date: 2006-05
Authors: Alan W Katz; Sheema Chawla; Zhenhong Qu; Randeep Kashyap; Michael T Milano; Aram F Hezel Journal: Int J Radiat Oncol Biol Phys Date: 2011-12-13 Impact factor: 7.038
Authors: Shaakir Hasan; Ngoc Thai; Tadahiro Uemura; Vijay Kudithipudi; Paul Renz; Stephen Abel; Alexander V Kirichenko Journal: World J Gastrointest Surg Date: 2017-12-27
Authors: Alicia Román-Jobacho; María Hernández-Miguel; María Jesús García-Anaya; Jaime Gómez-Millán; J A Medina-Carmona; Ana Otero-Romero Journal: J Clin Transl Res Date: 2021-05-27
Authors: Paul C Lyon; Helen Winter; Karin Herbschleb; Leticia Campo; Robert Carlisle; Feng Wu; Robert Goldin; Constantin C Coussios; Mark R Middleton; Fergus V Gleeson; Philip Boardman; Ricky A Sharma Journal: Radiol Case Rep Date: 2018-09-22